Ackermann, Mania
Saleh, Fawaz
Abdin, Shifaa M.
Rafiei Hashtchin, Anna
Gensch, Ingrid
Golgath, Julia
Carvalho Oliveira, Marco
Nguyen, Ariane H. H.
Gaedcke, Svenja
Fenske, Arno
Jang, Mi-Sun
Jirmo, Adan C.
Abeln, Markus
Hansen, Gesine
Lachmann, Nico http://orcid.org/0000-0002-4245-1497
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (LA 3680/9-1)
REBIRTH (ZN3340)
HORIZON EUROPE European Research Council (852178 101100859)
Medizinische Hochschule Hannover (MHH)
Article History
Received: 6 March 2024
Accepted: 6 June 2024
First Online: 18 June 2024
Declarations
:
: Human buffy coat blood was provided by ‘Deutsches Rotes Kreuz Niedersachsen’, with the prior informed consent of all respective donors. Generation of human iPSC (hCD34iPSC11) has been approved by the ethics committee of the Hannover medical school (No:7870_BO_K_2018). Generation of human iPSC (hHSC_Iso4_ADCF_SeViPS2) has been approved by the ethics committee of the Hannover medical school [].
: All consent and approval were taken from all authors and & co-authors.
: M.A. and N.L. are authors of the patent application (European patent application number PCT/EP2018/061574) entitled ‘Stem-cell derived myeloid cells, generation and use thereof’. The priority date of the application is 4 May 2017. N.L. and S.A. are authors on the patent application (European patent application number PCT/EP2021/083371) entitled ‘Application of stem cell derived monocytes in a Monocyte Activation Test (MAT) for the assessment of pyrogenicity and inflammatory potential’. The priority date of the application is 29 November 2021. All other authors declare no competing interests.